Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Reinhard Ding"'
Autor:
Walter E. Haefeli, Mahmoudreza Fardanesh, Reinhard Ding, Eva Frei, P. Kremer, Hans-Hermann Schrenk
Publikováno v:
The Journal of Clinical Pharmacology. 51:672-678
In a phase I/II study, the new fluorescence marker 5-aminofluorescein covalently bound to human serum albumin (AFL-HSA) was intravenously administered to 10 patients with brain tumor 1 to 4 days before surgery, and AFL-HSA kinetics were determined to
Autor:
M. Jäger, Gerd Mikus, Walter E. Haefeli, Jürgen Burhenne, Reinhard Ding, Anne‐Kathrin Matthee, Verena Hafner
Publikováno v:
Clinical Pharmacology & Therapeutics. 87:191-196
We aimed to assess the effect of coadministration and withdrawal of a potent cytochrome P450 3A (CYP3A) inhibitor (ritonavir) and a potent CYP3A inducer (St John's wort) on CYP3A enzyme activity in an open, fixed-sequence study design. We investigate
Publikováno v:
Operative Neurosurgery. 64:ons53-ons61
OBJECTIVE: The newly developed conjugate 5-aminofluorescein (AFL)-human serum albumin (HSA) was investigated in a clinical trial for fluorescence-guided surgery of malignant brain tumors to assess its efficacy and tolerability. METHODS: AFL, covalent
Autor:
Lenore Teichert, Andreas Hirschfeld-Warneken, Heike Oberwittler, Reinhard Ding, Walter E. Haefeli, Roland Wesch, Hans Willerich, Karl-Heinz Lehr, Gerd Mikus
Publikováno v:
The Journal of Clinical Pharmacology. 47:70-77
HMR1766 is a new nitric oxide (NO)-independent activator of soluble guanylyl cyclase (sGC) in development for the treatment of cardiovascular diseases and chronic heart failure. A significant fraction of patients to be treated with HMR1766 is expecte
Autor:
Magdalena Drzewinska, Johanna Weiss, Verena Schöwel, Reinhard Ding, Jürgen Burhenne, Jens Rengelshausen, Gerd Mikus, Klaus-Dieter Riedel, Walter E. Haefeli, T. Thomsen
Publikováno v:
Clinical Pharmacology & Therapeutics. 80:126-135
Objectives Cytochrome P450 (CYP) 2C19 and CYP3A4 are the major enzymes responsible for voriconazole elimination. Because the activity of CYP2C19 is under genetic control, the extent of inhibition with a CYP3A4 inhibitor was expected to be modulated b
Autor:
Gerd Mikus, Johanna Weiss, Jürgen Burhenne, Klaus-Dieter Riedel, Walter E. Haefeli, Yorki Tayrouz, Reinhard Ding
Publikováno v:
Clinical Pharmacology & Therapeutics. 76:73-84
Background Ritonavir is a potent in vitro inhibitor of several cytochrome P450 isozymes and ABC transporters including the efflux pump P-glycoprotein (P-gp). This study assessed the effect of repetitive ritonavir administration on digoxin distributio
Autor:
Reinhard Ding, Gerd Mikus, Meret Martin-Facklam, Ingeborg Walter-Sack, Ruth Fricker, Walter E. Haefeli, Jürgen Burhenne
Publikováno v:
British Journal of Clinical Pharmacology. 53:576-581
Aims Bioavailability of orally administered drugs depends on several factors including active excretion, e.g. by P-glycoprotein (PGP), and presystemic metabolism, e.g. by cytochrome P450 3A (CYP3A), in both gastrointestinal tract and liver. Many drug
Autor:
Walter E. Haefeli, Laila Schmidt, Reinhard Ding, Johanna Weiss, Jürgen Burhenne, Gerd Mikus, Yorki Tayrouz, Klaus-Dieter Riedel
Publikováno v:
Clinical pharmacokinetics. 43(14)
To assess any pharmacokinetic interactions between loperamide and saquinavir. Double-blind, double-dummy, randomised, placebo-controlled, three-way crossover trial. Twelve healthy male and female volunteers, aged 24–46 years. Methods: Saquinavir an
Autor:
Matthias Lang, Vera Hinke, Karl Wegscheider, Christof Clanget, Yorki Tayrouz, Ingeborg Walter-Sack, Johannes Pfeilschifter, Christoph Goeggelmann, Reinhard Ding
Publikováno v:
Clinical pharmacokinetics. 43(14)
Assessment of dosage form performance in delivering endogenous compounds, such as hormones, in vivo requires a specific approach. Assessment of relative bioavailability of levothyroxine sodium (L-T4) from eight solid preparations, compared with a liq
Autor:
Reinhard, Ding, Yorki, Tayrouz, Klaus-Dieter, Riedel, Jürgen, Burhenne, Johanna, Weiss, Gerd, Mikus, Walter E, Haefeli
Publikováno v:
Clinical pharmacology and therapeutics. 76(1)
Ritonavir is a potent in vitro inhibitor of several cytochrome P450 isozymes and ABC transporters including the efflux pump P-glycoprotein (P-gp). This study assessed the effect of repetitive ritonavir administration on digoxin distribution and total